GPC3-m28Z-mNFAT-mIL-12 T cells therapy (Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine)

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameGPC3-m28Z-mNFAT-mIL-12 T cells therapy (Renji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionGlypican-3 modulatorsT lymphocyte replacementsInterleukin-12 receptor modulators
TargetsGlypican-3Interleukin-12 receptor
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesRenji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesRenji Hospital Affiliated To Shanghai Jiaotong University School Of Medicine
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A